Hsing-Jien Kung Selected Research

Histone Demethylases

5/2022	Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
1/2021	Arginine starvation elicits chromatin leakage and cGAS-STING activation via epigenetic silencing of metabolic and DNA-repair genes.
10/2020	Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.
11/2019	Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
1/2019	KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis.
1/2016	KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
7/2014	KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
5/2010	KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hsing-Jien Kung Research Topics

Disease

79	Neoplasms (Cancer) 05/2022 - 11/2002
65	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 03/2002
14	Breast Neoplasms (Breast Cancer) 08/2021 - 02/2002
13	Neoplasm Metastasis (Metastasis) 12/2021 - 03/2004
9	Carcinogenesis 07/2021 - 12/2002
8	Starvation 01/2021 - 10/2011
7	Marek Disease (Marek's Disease) 08/2013 - 12/2003
5	Hypoxia (Hypoxemia) 01/2019 - 01/2014
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 09/2014
3	Lung Neoplasms (Lung Cancer) 01/2020 - 12/2002
3	Infections 01/2013 - 05/2004
2	Mouth Neoplasms (Oral Cancer) 05/2021 - 01/2017
2	Stomach Neoplasms (Stomach Cancer) 10/2020 - 01/2019
2	Genomic Instability 01/2019 - 07/2014
2	Carcinoma (Carcinomatosis) 01/2017 - 04/2008
2	Sarcoma (Soft Tissue Sarcoma) 12/2014 - 01/2004
2	Lymphoma (Lymphomas) 11/2013 - 11/2012
2	T-Cell Leukemia (Leukemia, T Cell) 11/2012 - 04/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2008 - 12/2007
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Bites and Stings (Sting) 01/2021
1	Pathologic Processes 05/2020
1	Muscular Atrophy (Muscle Atrophy) 01/2020

Drug/Important Bio-Agent (IBA)

35	AndrogensIBA 05/2022 - 03/2002
29	Androgen Receptors (Androgen Receptor)IBA 05/2022 - 03/2002
19	Proteins (Proteins, Gene)FDA Link 11/2019 - 12/2003
12	Arginine (L-Arginine)FDA Link 07/2021 - 10/2008
10	Phosphotransferases (Kinase)IBA 07/2021 - 02/2002
10	ChromatinIBA 01/2021 - 05/2010
10	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 12/2002
9	Hormones (Hormone)IBA 08/2021 - 12/2005
8	Histone DemethylasesIBA 05/2022 - 05/2010
8	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 01/2021 - 10/2008
8	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2007
7	EnzymesIBA 10/2016 - 10/2008
7	src-Family KinasesIBA 06/2012 - 01/2004
6	Small Interfering RNA (siRNA)IBA 09/2015 - 11/2004
6	LigandsIBA 01/2012 - 03/2002
5	Histones (Histone)IBA 01/2021 - 08/2006
5	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2002
5	arginine deiminaseIBA 09/2014 - 10/2008
5	Tyrosine (L-Tyrosine)FDA Link 02/2011 - 02/2002
5	saracatinibIBA 06/2010 - 04/2008
4	ErbB Receptors (EGF Receptor)IBA 08/2021 - 02/2002
4	Interleukin-6 (Interleukin 6)IBA 05/2016 - 08/2009
4	Tyrosine Kinase InhibitorsIBA 03/2013 - 03/2004
3	Biological ProductsIBA 05/2022 - 03/2004
3	enzalutamideIBA 05/2022 - 12/2015
3	Biomarkers (Surrogate Marker)IBA 08/2021 - 03/2013
3	Long Noncoding RNAIBA 05/2021 - 12/2014
3	Messenger RNA (mRNA)IBA 11/2019 - 12/2014
3	Interleukin-8 (Interleukin 8)IBA 01/2019 - 03/2004
3	Docetaxel (Taxotere)FDA Link 01/2018 - 01/2009
3	Glucose (Dextrose)FDA LinkGeneric 10/2016 - 01/2014
3	DNA (Deoxyribonucleic Acid)IBA 09/2014 - 05/2008
3	CaspasesIBA 05/2013 - 01/2009
3	NeuropeptidesIBA 01/2009 - 11/2006
3	ChemokinesIBA 11/2006 - 03/2004
3	Serine (L-Serine)FDA Link 04/2006 - 09/2004
2	Amino Acids FDA Link 07/2021 - 05/2013
2	Succinic Acid (Succinate)IBA 01/2020 - 06/2016
2	Estrogen ReceptorsIBA 10/2019 - 10/2011
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2019 - 01/2011
2	CholesterolIBA 10/2019 - 01/2011
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 10/2019 - 03/2007
2	Transcription Factors (Transcription Factor)IBA 08/2017 - 04/2006
2	Pharmaceutical PreparationsIBA 12/2015 - 08/2006
2	Lysine (L-Lysine)FDA Link 07/2014 - 08/2006
2	ADI PEG20IBA 04/2014 - 01/2009
2	Oncogene Proteins (Oncogene Protein)IBA 08/2013 - 12/2003
2	Basic-Leucine Zipper Transcription FactorsIBA 08/2013 - 02/2010
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2013 - 06/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2012 - 03/2004
2	CytokinesIBA 08/2012 - 11/2006
2	FlavonoidsIBA 07/2011 - 03/2004
2	Testosterone (Sustanon)FDA Link 01/2011 - 08/2009
2	CalpainIBA 01/2010 - 10/2007
2	VaccinesIBA 06/2009 - 03/2008
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2009 - 09/2006
2	Protein Kinases (Protein Kinase)IBA 09/2004 - 09/2002
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 05/2022
1	myricetinIBA 05/2022
1	etomoxirIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Oxygen (Dioxygen)IBA 12/2021
1	Pyruvate KinaseIBA 08/2021
1	IsoenzymesIBA 08/2021
1	Phenobarbital (Luminal)FDA Link 08/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2021
1	Immunologic Factors (Immunomodulators)IBA 07/2021
1	PolyaminesIBA 07/2021
1	Interferon Type IIBA 01/2021
1	InterferonsIBA 01/2021
1	Essential Amino AcidsIBA 01/2021
1	AgarIBA 11/2019

Therapy/Procedure

31	Therapeutics 05/2022 - 08/2004
21	Castration 05/2022 - 01/2009
4	Drug Therapy (Chemotherapy) 05/2013 - 05/2008
3	Radiotherapy 01/2022 - 12/2007
1	Radioimmunotherapy 01/2022